NEW EULAR POSTER: Real-world effectiveness of an IL-23i vs TNFi or IL-17i in PsA. 🔍Learn how these treatment choices impacted joint outcomes in biologic-naive patients. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/T3RJQEpJxy https://t.co/X5XSV8O6ey

Leeds study of 44 patients idiopathic inflamm myopathy (IIM) pts Rx w/ rituximab showed a 70% response 4-6 mos post RTX. Responders had higher TIS (50·0 vs 17·5). Using highly sensitive flow cytometry, @ 2 wks responders had lower #s memory B cells & Plasmablasts. Is there a role https://t.co/HTxOIxkezs

Swedish study of 1097 #RA pts looked at modifiable healthy lifestyle habits (HLHs: EtOH use, smoking, physical activity). At Baseline, 56% had three HLHs , unchanged (58%) at Yr 3. Nonsmoking incr 77-83%, healthy alcohol from 85%-97%. but healthy PA decr 84-71%. Lifestyle modif. https://t.co/cDyQwiN6Ae

ACP Clinical Guideline on Treatments of Overweight or Obese Adults In July 2026, ACP published its first living clinical guideline addressing pharmacologic management of overweight and obesity in nonpregnant adults in outpatient settings. As this therapeutic area is rapidly https://t.co/5oQIY7J2Aw

Music and Pain Relief A new scoping review in Pain Reports by Bradt et al., examines the effect of MBIs on pain management. While its efficacy is well established, how or why music relieves pain has never been fully explained. This systematic review is based on 663 records and https://t.co/HBCURxB9WC

EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk https://t.co/1jAvPfRI0m

Join us for the first of four webinars this month! This Journal Club will explore the TOGETHER PsA and STEP 9 trials, and what emerging evidence tells us about the complex relationship between obesity, weight loss and rheumatic disease. The authors and leading experts will: • https://t.co/xpnqim1VKH

12 mos Danish study of 157 822 first-time semaglutide for obesity management (SOM) intiators. 77 483 discontinued treatment w/in 12 mos. (13% at 3 mo, 27% 6 mos, 39% @ 9 mos. D/C more likely in younger, men, low-income, on GI or psych meds, & pts with comorbididities. Few https://t.co/oJLnrxXFz0

Swedish Pt Registry of 4317 AAV pts showed GPA & MPA had signif incr risk of CV dz (HR 2.04) & thromboembolism (HR 2.45); males incr MI risk (HR 2.25) & females incr ischemic stroke risk (HR 1.64). Sibs had no excess CVD-TE risk. The highest CVD-TE risk occurred within 3 mos. of https://t.co/FdbIXoCZf0

Join us for the first of four webinars this month! Our Journal Club explores the TOGETHER PsA and STEP 9 trials, and what emerging evidence reveals about obesity, weight loss and rheumatic disease. Featuring Drs. Philip Mease, Tom Appleton and Jack Cush. https://t.co/KkVJPyhKF1

True or False: In a Korean National Health Insurance study, gout patients on allopurinol had a significantly higher risk of fractures, with the highest risk seen in those with low adherence. Did you get it right? Take this week's RheumIQ and see: https://t.co/UaXqHKWizt. https://t.co/7nILMVUeGw